Full history for every metric is available with a Kvantra account
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 584 | 649 | 821 | 899 | 957 | 986 | 1,017 | 1,038 |
| Operating profit | €m | 176 | 149 | ||||||
| Net profit | €m | 77 | 101 | 125 | 152 | 150 | 146 | 137 | 151 |
| EPS reported | € | 0.97 | 0.91 | ||||||
| Operating cashflow per share | € | 1.19 | 1.29 | ||||||
| Capex per share | € | 0.96 | 0.92 | ||||||
| FCF per share | € | 0.23 | 0.37 | ||||||
| Free cash flow | €m | 35.2 | 55.3 | ||||||
| Net debt | €m | -26 | 206 | ||||||
| Book value equity | €m | 892 | 996 | ||||||
| Book value per share | € | 5.92 | 6.67 | ||||||
| Number of shares | m | 150.62 | 149.34 | ||||||
| DPS (TTM paid) | € | 0.18 | 0.18 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 21.75 | 26.32 | ||||||
| P/B LTM | x | 3.56 | 3.61 | ||||||
| P/S LTM | x | 3.22 | 3.54 | ||||||
| P/FCF LTM | x | 90.38 | 65.06 | ||||||
| EV/EBITDA LTM | x | 11.86 | 15.55 | ||||||
| EV/Sales LTM | x | 3.28 | 3.74 | ||||||
| Earnings Yield LTM | % | 4.60% | 3.80% | ||||||
| FCF Yield | % | 1.11% | 1.54% | ||||||
| Quality | |||||||||
| ROE | % | 16.42% | 14.53% | ||||||
| ROIC | % | 11.57% | 7.88% | ||||||
| Operating margin | % | 17.84% | 14.63% | ||||||
| Gross margin | % | 33.71% | 31.19% | ||||||
| FCF/Sales | % | 3.57% | 5.44% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -2.02% | -7.14% | ||||||
| Sales Growth YoY | % | +3.04% | +4.28% | ||||||
| Net Income Growth YoY | % | -2.16% | -7.01% | ||||||
| FCF Growth | % | -56.06% | +11.61% | ||||||
| Operating Profit Growth | % | -8.66% | -26.93% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.76% | 0.75% | ||||||
| Dividend Growth | % | +12.50% | +12.50% | ||||||
| Payout Ratio | % | 16.49% | 19.82% | ||||||
| FCF/Debt | x | 0.42 | 0.24 | ||||||
| Net Debt/EBITDA | x | 0.22 | 0.84 | ||||||
| EBIT/Net interest | x | 8.91 | 11.05 | ||||||
| Net debt/market cap | % | -0.81% | 5.74% | ||||||
| Net debt/Equity | x | -0.03 | 0.21 | ||||||
| Gross debt/equity | x | 0.09 | 0.23 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Globally, SCHOTT Pharma AG & Co. KGaA specializes in the development, manufacturing, and distribution of sophisticated containment and delivery systems specifically designed for injectable pharmaceuticals, catering to the needs of the pharmaceutical and biotechnology sectors. Their comprehensive product portfolio encompasses both polymer and glass options across various crucial categories, including syringes, ampoules, vials, and cartridges. Their extensive range of syringes features specialized solutions such as the syriQ series (including BioPure for biologics and silicone-free variants) crafted from glass, ideal for vaccines and sensitive biologics, alongside the versatile polymer-based SCHOTT TOPPAC line, tailored for applications from cosmetic treatments and deep-cold storage to infusion therapy and delicate drugs. For cartridges, SCHOTT Pharma provides the cartriQ pharmaceutical glass series, designed for peptide, protein, and large-volume injectables, as well as double-chamber options for lyophilized drugs and break-resistant variants, supplemented by their TopLine and StandardLine offerings. Vial solutions include the adaptiQ pharmaceutical glass vial for general injectables, the EVERIC range focused on drug stability (pure, care for pH, strong & smooth for filling lines), SCHOTT Type I plus for specific formulations, and TopLyo to prevent fogging in lyophilized drugs, alongside their TopLine and StandardLine vials. The ampoule selection features easyOPC for convenient opening, Anti-Counterfeiting ampoules for enhanced security, and their dependable StandardLine options. Established in 1884 and based in Mainz, Germany, SCHOTT Pharma AG & Co. KGaA functions as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
SCHOTT Pharma AG & Co. KGaA (1SXP.F)
Based on consensus from external analysts. Not Kvantra's opinion.
Globally, SCHOTT Pharma AG & Co. KGaA specializes in the development, manufacturing, and distribution of sophisticated containment and delivery systems specifically designed for injectable pharmaceuticals, catering to the needs of the pharmaceutical and biotechnology sectors. Their comprehensive product portfolio encompasses both polymer and glass options across various crucial categories, including syringes, ampoules, vials, and cartridges. Their extensive range of syringes features specialized solutions such as the syriQ series (including BioPure for biologics and silicone-free variants) crafted from glass, ideal for vaccines and sensitive biologics, alongside the versatile polymer-based SCHOTT TOPPAC line, tailored for applications from cosmetic treatments and deep-cold storage to infusion therapy and delicate drugs. For cartridges, SCHOTT Pharma provides the cartriQ pharmaceutical glass series, designed for peptide, protein, and large-volume injectables, as well as double-chamber options for lyophilized drugs and break-resistant variants, supplemented by their TopLine and StandardLine offerings. Vial solutions include the adaptiQ pharmaceutical glass vial for general injectables, the EVERIC range focused on drug stability (pure, care for pH, strong & smooth for filling lines), SCHOTT Type I plus for specific formulations, and TopLyo to prevent fogging in lyophilized drugs, alongside their TopLine and StandardLine vials. The ampoule selection features easyOPC for convenient opening, Anti-Counterfeiting ampoules for enhanced security, and their dependable StandardLine options. Established in 1884 and based in Mainz, Germany, SCHOTT Pharma AG & Co. KGaA functions as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free